Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological - 63rd ASH Annual Meeting and Exposition - Onlineportal für Onkologie und Hämatologie

Monoclonal Gammopathies of Determined Significance: What We Have and What We Want
A Map for the Changing Landscape of Multiple Myeloma
Multiple Myeloma and Waldenstrom Macroglobulinemia: Exploring Biomarkers in the Era of Personalized Medicine
Reoptimizing Standards and Redefining Approaches
Challenges in Multiple Myeloma Therapy: Adopting New Approaches for Relapse and Monitor

652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Monoclonal Gammopathies of Determined Significance: What We Have and What We Want

151

Prevalence of Smoldering Multiple Myeloma: Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

Sigrun Thorsteinsdottir, Gauti Kjartan Gislason, Thor Aspelund, et al.

See abstract for more info.

152

High Prevalence of Monoclonal Gammopathy in a Population at Risk: The First Results of the Promise Study

Habib El-Khoury, Jean-Baptiste Alberge, Hadley Barr, et al.

See abstract for more info.

153

Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients

Giovanni Palladini, Stefan Schönland, Giampaolo Merlini, et al.

See abstract for more info.

154

Monoclonal Gammopathy of Undetermined Significance and COVID-19: Results from the Population-Based Iceland Screens Treats or Prevents Multiple Myeloma Study (iStopMM)

Sæmundur Rögnvaldsson, Elias Eythorsson, Sigrun Thorsteinsdottir, et al.

See abstract for more info.

155

A 40-Year Natural History Study of Overall Survival and Primary Causes of Death in Systemic Light Chain (AL) Amyloidosis

Andrew Staron, Luke Zheng, Gheorghe Doros, et al.

See abstract for more info.

156

Screening for Monoclonal Gammopathy of Undetermined Significance: A Population-Based Randomized Clinical Trial. First Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

Sigurdur Y Kristinsson, Sæmundur Rögnvaldsson, Sigrun Thorsteinsdottir, et al.

See abstract for more info.

652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: A Map for the Changing Landscape of Multiple Myeloma

397

FISH and WGS in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma – WGS Will Affect Future Treatment Decisions

Marietta Truger, Stephan Hutter, Manja Meggendorfer, et al.

See abstract for more info.

398

Molecular Features and Clinical Outcomes of Extramedullary Plasmacytomas

Rie Nakamoto-Matsubara, MD, PhD^1,2^*, Valentina Nardi, MD^1,3, Cristina Panaroni, et al.

See abstract for more info.

399

Pathogenic Germline Variants in Multiple Myeloma

Santiago Thibaud, Aaron Etra, Ryan Subaran, et al.

See abstract for more info.

400

Inadequate Sars-Cov-2 Vaccine Effectiveness in Patients with Multiple Myeloma: A Large Nationwide Veterans Affairs Study

Nathanael R Fillmore, Jennifer La, Julie Tsu-Yu Wu, et al.

See abstract for more info.

401

Characterization of T-Cell Exhaustion in Rapid Progressing Multiple Myeloma Using Cross Center Scrna-Seq Study

William Pilcher, Beena E Thomas, Swati S Bhasin, et al.

See abstract for more info.

402

Racial and Ethnic Differences in Clonal Hematopoiesis, Tumor Markers, and Clinical Outcomes of Patients with Multiple Myeloma

Nancy Gillis, Lauren C Peres, Christelle M Colin-Leitzinger, et al.

See abstract for more info.

652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Multiple Myeloma and Waldenstrom Macroglobulinemia: Exploring Biomarkers in the Era of Personalized Medicine

457

Transcriptomic Correlates of Response to Selinexor in Multiple Myeloma Reveal a Predictive Signature

Paula Restrepo, Sherry Bhalla, Adolfo Aleman, et al.

See abstract for more info.

458

Loss of COP9 Signalosome Gene-Containing 2q Region Is Associated with Lenalidomide and Pomalidomide Resistance in Myeloma Patients

Sarah Gooding, Naser Ansari-Pour, Mohammad H Kazeroun, et al.

See abstract for more info.

459

Identification of a Novel Drug Sensitivity Biomarker Neuregulin-2 for Venetoclax in Non-t(11;14) Multiple Myeloma

Yujun Dai, MD, PhD¹^*, Xue-Ping Li²^*, Fang Hu³^*, et al.

See abstract for more info.

460

Myeloma Patients with Deletion of 17p: Impact of Tandem Transplant and Clone Size

Alfredo De La Torre, Eshetu G Atenafu, Adam C. Smith, et al.

See abstract for more info.

461

Presence of Extrachromosomal DNA (ecDNA) Impacts Both Progression Free and Overall Survival and Is an Independent Poor Prognostic Marker in Multiple Myeloma

Parth Shah, Anil Aktas-Samur, Mariateresa Fulciniti, et al.

See abstract for more info.

462

Prognostic Impact of MYD88 L265P Mutation By Droplet Digital PCR in IgM MGUS and Smoldering Waldenström Macroglobulinemia

David F. Moreno, Sara Paz, Mari-Pau Mena, et al.

See abstract for more info.

652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Reoptimizing Standards and Redefining Approaches

541

Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies

Leire Burgos, Luis Esteban Tamariz-Amador, Noemí Puig, et al.

See abstract for more info.

542

Defining New Reference Intervals for Serum Free Light Chains in Individuals with Reduced Kidney Function: Results of the Population- Based on Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM) Study

Thorir Einarsson Long, Olafur Skuli Indridason, Runolfur Palsson, et al.

See abstract for more info.

543

Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis

Alissa Visram, S. Vincent Rajkumar, Prashant Kapoor, et al.

See abstract for more info.

544

Assessment of Treatment Response By Ife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial

Noemi Puig, Teresa Contreras Sanfeliciano, Bruno Paiva, et al.

See abstract for more info.

545

Defining Genomic Probability of Progression to Identify Low-Risk Smoldering Multiple Myeloma

Anil Aktas-Samur, Mariateresa Fulciniti, Sanika Derebail, et al.

See abstract for more info.

546

Circulating Plasma Cells Are the Most Powerful Prognostic Marker in Transplant Ineligible Multiple Myeloma with 2% As a New Cut-Off for Primary Plasma Cell Leukemia

Tomas Jelinek, Renata Bezděková, David Zihala, et al.

See abstract for more info.

652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Challenges in Multiple Myeloma Therapy: Adopting New Approaches for Relapse and Monitor

817

Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in Patients with t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, Hang Quach, Rachid Baz, et al.

A tolerable safety profile was observed in t t (11; 14) -selected RRMM patients who were treated with VenDd vs. DVd. Updated analyzes will be presented in the oral session.

818

High-Dose Carfilzomib Recaptures Response in Relapsed/Refractory Multiple Myeloma Resistant to Low-Dose Carfilzomib By Co-Inhibiting β2 Subunit of Proteasome Complex: The First in Human Evidence

Xiang Zhou¹^*, Andrej Besse²^*, Jessica Peter, et al.

High-dose CFZ (≥ 36 mg / m2) achieved a more effective inhibition of the proteasome by blocking the β5 and β2 subunits. Inadequate inhibition of the β2 subunit was achieved with low-dose CFZ. The authors thus prove that high-dose CFZ could regain the response in RRMM patients - resistant to low-dose CFZ - by co-inhibiting the β2 subunit activity of the proteasome complex.

819

Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience

Sarah Goldman-Mazur, Alissa Visram, S Vincent Rajkumar, et al.

See abstract for more info.

820

Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment

Hannah Victoria Giles, Mark T Drayson, Nicola Wright, et al.

See abstract for more info.

821

Clinical Outcomes of Relapsed/Refractory Multiple Myeloma Patients Following Treatment with Bispecific Antibodies (BiAbs)

Tarek H. Mouhieddine, Oliver Van Oekelen, Darren Pan, et al.

See abstract for more info.

822

Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment

Oliver Van Oekelen, Sarita Agte, Adolfo Aleman, et al.

See abstract for more info.